Company Encyclopedia
View More
name
Sanyou Medical
688085.SH
Shanghai Sanyou Medical Co., Ltd. researches, develops, manufactures, and sells orthopedics implants in China. The company offers spinal and trauma implants under Tytus and Sanyou brand. Its spinal products comprise anterior cervical plate, anterior thoracolumbar, posterior cervical, posterior thoracolumbar, and z-minimally invasive products; and trauma implants, including shoulder and elbow system, hip and pelvis system, knee system, foot and ankle, knee system, and palm and wrist systems.
932.45 B
688085.SHMarket value -Rank by Market Cap -/-

Financial Score

08/11/2025 Update
B
Health Care EquipmentIndustry
Industry Ranking17/63
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreB
    • ROE3.26%C
    • Profit Margin12.66%B
    • Gross Margin82.41%A
  • Growth ScoreB
    • Revenue YoY17.99%B
    • Net Profit YoY71.34%A
    • Total Assets YoY2.49%C
    • Net Assets YoY2.41%C
  • Cash ScoreB
    • Cash Flow Margin789.66%B
    • OCF YoY17.99%B
  • Operating ScoreD
    • Turnover0.22D
  • Debt ScoreA
    • Gearing Ratio10.57%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Innovation + Going Global, Highlights of Biopharmaceutical Companies' Q3 Reports

    As of October 28, over 280 listed pharmaceutical and biotechnology companies, including Hengrui Pharma, HUADONG MEDICINE, WuXi AppTec, and Sanyou Medical, have disclosed their Q3 2025 reports, with many companies presenting impressive "report cards." Several pharmaceutical companies have achieved double growth in revenue and profit through the advancement of their R&D pipelines and the launch of innovative drugs, while breakthroughs in overseas business have injected new momentum into their performance. The industry as a whole is showing a positive development trend of "innovation as the foundation and expanding overseas." (Shanghai Securities Journal)

    Wallstreetcn·
    SH
    603259
    -0.89%
    HK
    02359
    -2.00%
    SH
    688085
    +0.91%
    Wallstreetcn·
    SH
    603259
    -0.89%
    HK
    02359
    -2.00%
    SH
    688085
    +0.91%

    Shanghai Sanyou Medical received a government subsidy of 1.405 million, accounting for 12.25% of last year's net profit

    Shanghai Sanyou Medical Devices Co., Ltd. announced that it recently received a government subsidy of 1.405 million yuan, accounting for 12.25% of the audited net profit attributable to shareholders of the listed company for the year 2024. This subsidy is a government grant related to income, and the specific accounting treatment and its impact on the company's annual profit and loss will be subject to the confirmation results of the auditing agency. The company's board of directors reminds investors to pay attention to investment risks

    Zhitong·
    SH
    688085
    +0.91%
    Zhitong·
    SH
    688085
    +0.91%

    Sanyou Medical grants 4.782 million restricted shares to 55 incentive recipients

    According to the Zhitong Finance APP, Sanyou Medical announced that the company has reviewed and approved the proposal on granting restricted stocks to the incentive objects of the 2025 restricted stock incentive plan, determining September 26, 2025, as the grant date, and granting 4.782 million shares of restricted stock at a grant price of 11.12 yuan per share to 55 eligible incentive objects

    Zhitong·
    SH
    688085
    +0.91%
    Zhitong·
    SH
    688085
    +0.91%

    Sanyou Medical: The preliminary inquiry transfer price is set at RMB 18.11 per share

    According to the Zhitong Finance APP, Sanyou Medical disclosed the pricing situation for the inquiry transfer by shareholders. Based on the inquiry subscription situation on September 23, 2025, the preliminary determined price for this inquiry transfer is RMB 18.11 per share. The shares intended for transfer in this inquiry have been fully subscribed, and the preliminary determined transferees are six institutional investors, with a total number of shares to be transferred amounting to 6.66925 million shares

    Zhitong·
    SH
    688085
    +0.91%
    Zhitong·
    SH
    688085
    +0.91%

    Sanyou Medical shareholders plan to inquire about the transfer of 2% of shares

    According to the Zhitong Finance APP, Sanyou Medical has released a shareholder inquiry transfer plan, with the participating shareholder being QM5 LIMITED, intending to transfer a total of 6.66925 million shares, accounting for 2% of the company's total share capital

    Zhitong·
    SH
    688085
    +0.91%
    Zhitong·
    SH
    688085
    +0.91%